Tonix Announces Pricing for New $20M Direct Offering
Tonix Pharmaceuticals has secured approximately $20 million in gross proceeds through a direct offering to Point72, selling 615,025 common...
eClinical Tech News
Tonix Reveals New Hope for Seasonal Lyme Disease Prevention
Tonix Pharmaceuticals has outlined a 2026 FDA engagement to shape a Phase 2/3 path for TNX-4800, a long-acting monoclonal...
Genmab Announces Closing of Senior Notes Private Offering
Genmab has closed a $2.5 billion notes offering—$1.5 billion of 6.250% senior secured notes due 2032 and $1.0 billion...
NKGen Biotech Issues Statement on Affiliate Board Changes
NKGen Biotech’s majority-owned subsidiary in Seoul has overhauled its governance and identity. NKGen Biotech Korea, formerly NKMAX, completed a...
A Complete Look at Tempest’s Q3 2025 Financial Results
Tempest Therapeutics reported third-quarter 2025 results and moved further into a formal review of strategic alternatives, effectively shifting from...
Senseonics’ Latest Third Quarter Financial Results Reported
Senseonics reported third-quarter 2025 revenue of $8.1 million, up 90% year over year, as U.S. new patient starts jumped...
ElectroCore Delivers Third Quarter 2025 Financial Results
ElectroCore posted record third-quarter 2025 revenue of $8.7 million, up 33% year over year, and lifted full-year guidance to...
XOMA Royalty’s Surging New Agreement to Acquire Gen Bio
XOMA Royalty Corporation will acquire Generation Bio for $4.2913 per share in cash, plus a contingent value right that...
Humacyte Publishes Long-Term Symvess® Trauma Repair Data
Humacyte has published the first prospective long-term outcomes for its off-the-shelf biologic vascular conduit, Symvess, in extremity arterial trauma,...
Galapagos Reports 2025 Financial Results & Business Update
Galapagos will wind down its cell therapy business following a strategic review and reported a nine‑month 2025 net loss...